SCHEMBL23906207

SCHEMBL23906207

CC(C)c1c(N2CCC(C(=O)O)CC2)nc2cc(N)c(C=N)cc2c1-c1ccc(F)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN9A Q15858 2/20 0.40
RHOA P61586 1/20 0.39
ALDH1A1 P00352 2/20 0.38
CYP1A2 P05177 2/20 0.38
CLK4 Q9HAZ1 2/20 0.38
HSD17B10 Q99714 2/20 0.37
KDM4E B2RXH2 1/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 1/20 0.37
CASP1 P29466 1/20 0.37
CASP7 P55210 1/20 0.37
NEK2 P51955 6/20 0.36
CYP2C9 P11712 1/20 0.36
RXFP1 Q9HBX9 2/20 0.35
PPARG P37231 1/20 0.35
ATM Q13315 1/20 0.35
NCOR2 Q9Y618 1/20 0.35
CYP3A4 P08684 1/20 0.35
HPGD P15428 1/20 0.35
S1PR1 P21453 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30252012 0.79 SCN9A (0.39) SCN9ARHOAALDH1A1CYP1A2CLK4
SCHEMBL23884427 0.79 SCN9A (0.39) SCN9ARHOAALDH1A1CYP1A2CLK4
SCHEMBL23895840 0.77 NOTUM (0.44) SCN9ARHOAALDH1A1CYP1A2CLK4
SCHEMBL23896411 0.77 NOTUM (0.44) SCN9ARHOAALDH1A1CYP1A2CLK4
SCHEMBL23895838 0.77 NOTUM (0.44) SCN9ARHOAALDH1A1CYP1A2CLK4
SCHEMBL23906083 0.76 DHODH (0.41) ALDH1A1KDM4EGAAHPGD
SCHEMBL23906123 0.76 SCN9A (0.38) SCN9ACYP2C9CYP3A4
SCHEMBL23905555 0.74 TNIK (0.42) SCN9A
SCHEMBL23884643 0.74 NOTUM (0.40) SCN9AALDH1A1CYP1A2CLK4HSD17B10
SCHEMBL23906194 0.74 NOTUM (0.40) SCN9AALDH1A1CYP1A2CLK4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021203025-A1 1 H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1 H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-10-07 WO disclosed